HSIC News & Events

Henry Schein entered into a new exclusive distribution agreement with CytoChip for its flagship product, the CitoCBC system, a U.S. Food and Drug Administration 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.

Henry Schein announced the appointment of Frederick Lowery as its new CEO, effective March 2, at which time he will join the board of directors. Lowery succeeds Stanley Bergman, who will step down as CEO after 35 years and continue to serve as chairman of the board to ensure a transition.